• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. May 15, 1996; 97(10): 2299–2307.
PMCID: PMC507310

A femtomolar-acting neuroprotective peptide.

Abstract

A novel 14-amino acid peptide, with stress-protein-like sequences, exhibiting neuroprotection at unprecedented concentrations, is revealed. This peptide prevented neuronal cell death associated with the envelope protein (GP 120) from HIV, with excitotoxicity (N-methyl d-aspartate), with the beta amyloid peptide (putative cytotoxin in Alzheimer's disease), and with tetrodotoxin (electrical blockade). The peptide was designed to contain a sequence derived from a new neuroprotective protein secreted by astroglial cells in the presence of vasoactive intestinal peptide. The neurotrophic protein was isolated by sequential chromatographic methods combining ion exchange, size separation, and hydrophobic interaction. The protein (mol mass, 14 kD and pI, 8.3 +/- 0.25) was named activity-dependent neurotrophic factor, as it protected neurons from death associated with electrical blockade. Peptide sequencing led to the synthesis of the novel 14-amino acid peptide that was homologous, but not identical, to an intracellular stress protein, heat shock protein 60. Neutralizing antiserum to heat shock protein 60 produced neuronal cell death that could be prevented by cotreatment with the novel protein, suggesting the existence of extracellular stress-like proteins with neuroprotective properties. These studies identify a potent neuroprotective glial protein and an active peptide that provide a basis for developing treatments of currently intractable neurodegenerative diseases.

Full Text

The Full Text of this article is available as a PDF (219K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Levi-Montalcini R. Recent studies on the NGF-target cells interaction. Differentiation. 1979;13(1):51–53. [PubMed]
  • Lin LF, Mismer D, Lile JD, Armes LG, Butler ET, 3rd, Vannice JL, Collins F. Purification, cloning, and expression of ciliary neurotrophic factor (CNTF). Science. 1989 Nov 24;246(4933):1023–1025. [PubMed]
  • Walicke PA, Baird A. Internalization and processing of basic fibroblast growth factor by neurons and astrocytes. J Neurosci. 1991 Jul;11(7):2249–2258. [PubMed]
  • Ishii DN, Glazner GW, Pu SF. Role of insulin-like growth factors in peripheral nerve regeneration. Pharmacol Ther. 1994 Apr-May;62(1-2):125–144. [PubMed]
  • Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, Thoenen H, Barde YA. Molecular cloning and expression of brain-derived neurotrophic factor. Nature. 1989 Sep 14;341(6238):149–152. [PubMed]
  • Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993 May 21;260(5111):1130–1132. [PubMed]
  • Henderson CE, Camu W, Mettling C, Gouin A, Poulsen K, Karihaloo M, Rullamas J, Evans T, McMahon SB, Armanini MP, et al. Neurotrophins promote motor neuron survival and are present in embryonic limb bud. Nature. 1993 May 20;363(6426):266–270. [PubMed]
  • Brenneman DE, Schultzberg M, Bartfai T, Gozes I. Cytokine regulation of neuronal survival. J Neurochem. 1992 Feb;58(2):454–460. [PubMed]
  • Patterson PH. The emerging neuropoietic cytokine family: first CDF/LIF, CNTF and IL-6; next ONC, MGF, GCSF? Curr Opin Neurobiol. 1992 Feb;2(1):94–97. [PubMed]
  • Brenneman DE, Neale EA, Habig WH, Bowers LM, Nelson PG. Developmental and neurochemical specificity of neuronal deficits produced by electrical impulse blockade in dissociated spinal cord cultures. Brain Res. 1983 Jul;285(1):13–27. [PubMed]
  • Brenneman DE, Fitzgerald S, Nelson PG. Interaction between trophic action and electrical activity in spinal cord cultures. Brain Res. 1984 Aug;317(2):211–217. [PubMed]
  • Agoston DV, Eiden LE, Brenneman DE, Gozes I. Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures. Brain Res Mol Brain Res. 1991 Jun;10(3):235–240. [PubMed]
  • Brenneman DE, Eiden LE, Siegel RE. Neurotrophic action of VIP on spinal cord cultures. Peptides. 1985;6 (Suppl 2):35–39. [PubMed]
  • Brenneman DE, Eiden LE. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc Natl Acad Sci U S A. 1986 Feb;83(4):1159–1162. [PMC free article] [PubMed]
  • Mutt V. Vasoactive intestinal polypeptide and related peptides. Isolation and chemistry. Ann N Y Acad Sci. 1988;527:1–19. [PubMed]
  • Said SI. VIP and messenger plasticity. Trends Neurosci. 1994 Aug;17(8):339–339. [PubMed]
  • Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, Brenneman DE. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther. 1991 Jun;257(3):959–966. [PubMed]
  • Brenneman DE, Neale EA, Foster GA, d'Autremont SW, Westbrook GL. Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J Cell Biol. 1987 Jun;104(6):1603–1610. [PMC free article] [PubMed]
  • Brenneman DE, Nicol T, Warren D, Bowers LM. Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J Neurosci Res. 1990 Mar;25(3):386–394. [PubMed]
  • Brenneman DE, Hill JM, Glazner GW, Gozes I, Phillips TW. Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival. Int J Dev Neurosci. 1995 Jun-Jul;13(3-4):187–200. [PubMed]
  • Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature. 1988 Oct 13;335(6191):639–642. [PubMed]
  • Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M, Brenneman DE. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):427–432. [PMC free article] [PubMed]
  • Brenneman DE, McCune SK, Gozes I. Acquired immune deficiency syndrome and the developing nervous system. Int Rev Neurobiol. 1990;32:305–353. [PubMed]
  • Everall IP, Luthert PJ, Lantos PL. Neuronal loss in the frontal cortex in HIV infection. Lancet. 1991 May 11;337(8750):1119–1121. [PubMed]
  • Schneider J, Kaaden O, Copeland TD, Oroszlan S, Hunsmann G. Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. J Gen Virol. 1986 Nov;67(Pt 11):2533–2538. [PubMed]
  • Hill JM, Mervis RF, Avidor R, Moody TW, Brenneman DE. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res. 1993 Feb 19;603(2):222–233. [PubMed]
  • Lipton SA, Sucher NJ, Kaiser PK, Dreyer EB. Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron. 1991 Jul;7(1):111–118. [PubMed]
  • Gozes I, Reshef A, Salah D, Rubinraut S, Fridkin M. Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment. Endocrinology. 1994 May;134(5):2121–2125. [PubMed]
  • Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, Davidson A, Rubinraut S, Fridkin M, Brenneman DE. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther. 1995 Apr;273(1):161–167. [PubMed]
  • Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7247–7251. [PMC free article] [PubMed]
  • Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 1993 Oct;16(10):403–409. [PubMed]
  • Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9649–9653. [PMC free article] [PubMed]
  • Shapira J. Research trends in Alzheimer's disease. J Gerontol Nurs. 1994 Apr;20(4):4–9. [PubMed]
  • Brumback RA, Leech RW. Alzheimer's disease: pathophysiology and the hope for therapy. J Okla State Med Assoc. 1994 Mar;87(3):103–111. [PubMed]
  • Nordberg A, Lilja A, Lundqvist H, Hartvig P, Amberla K, Viitanen M, Warpman U, Johansson M, Hellström-Lindahl E, Bjurling P, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging. 1992 Nov-Dec;13(6):747–758. [PubMed]
  • Nordberg A. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET. Acta Neurol Scand Suppl. 1993;149:62–65. [PubMed]
  • McCarthy KD, Partlow LM. Preparation of pure neuronal and non-neuronal cultures from embryonic chick sympathetic ganglia: a new method based on both differential cell adhesiveness and the formation of homotypic neuronal aggregates. Brain Res. 1976 Sep 24;114(3):391–414. [PubMed]
  • Schmechel D, Marangos PJ, Zis AP, Brightman M, Goodwin FK. Brain endolases as specific markers of neuronal and glial cells. Science. 1978 Jan 20;199(4326):313–315. [PubMed]
  • Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. [PubMed]
  • McManaman JL, Crawford FG, Stewart SS, Appel SH. Purification of a skeletal muscle polypeptide which stimulates choline acetyltransferase activity in cultured spinal cord neurons. J Biol Chem. 1988 Apr 25;263(12):5890–5897. [PubMed]
  • Venner TJ, Gupta RS. Nucleotide sequence of rat hsp60 (chaperonin, GroEL homolog) cDNA. Nucleic Acids Res. 1990 Sep 11;18(17):5309–5309. [PMC free article] [PubMed]
  • Gozes I, Brenneman DE. VIP: molecular biology and neurobiological function. Mol Neurobiol. 1989 Winter;3(4):201–236. [PubMed]
  • Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993 Apr;13(4):1676–1687. [PubMed]
  • Zeilstra-Ryalls J, Fayet O, Georgopoulos C. The universally conserved GroE (Hsp60) chaperonins. Annu Rev Microbiol. 1991;45:301–325. [PubMed]
  • Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet. 1988;22:631–677. [PubMed]
  • Uney JB, Kew JN, Staley K, Tyers P, Sofroniew MV. Transfection-mediated expression of human Hsp70i protects rat dorsal root ganglian neurones and glia from severe heat stress. FEBS Lett. 1993 Nov 22;334(3):313–316. [PubMed]
  • Cavanagh AC, Morton H. The purification of early-pregnancy factor to homogeneity from human platelets and identification as chaperonin 10. Eur J Biochem. 1994 Jun 1;222(2):551–560. [PubMed]
  • Hightower LE, Guidon PT., Jr Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. J Cell Physiol. 1989 Feb;138(2):257–266. [PubMed]
  • Prabhakar S, Kurien E, Gupta RS, Zielinski S, Freedman MS. Heat shock protein immunoreactivity in CSF: correlation with oligoclonal banding and demyelinating disease. Neurology. 1994 Sep;44(9):1644–1648. [PubMed]
  • Harrison PJ, Procter AW, Exworthy T, Roberts GW, Najlerahim A, Barton AJ, Pearson RC. Heat shock protein (hsx70) mRNA expression in human brain: effects of neurodegenerative disease and agonal state. Neuropathol Appl Neurobiol. 1993 Feb;19(1):10–21. [PubMed]
  • Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995 Jun 16;270(24):14255–14258. [PubMed]
  • Letourneur F, Klausner RD. A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell. 1992 Jun 26;69(7):1143–1157. [PubMed]
  • Dreyer EB, Kaiser PK, Offermann JT, Lipton SA. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science. 1990 Apr 20;248(4953):364–367. [PubMed]
  • Brorson JR, Bindokas VP, Iwama T, Marcuccilli CJ, Chisholm JC, Miller RJ. The Ca2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. J Neurobiol. 1995 Mar;26(3):325–338. [PubMed]
  • Carette B, Poulain P, Delacourte A. Electrophysiological effects of 25-35 amyloid-beta-protein on guinea-pig lateral septal neurons. Neurosci Lett. 1993 Mar 5;151(1):111–114. [PubMed]
  • Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992 Feb;12(2):376–389. [PubMed]
  • Valerio A, Alberici A, Paterlini M, Grilli M, Galli P, Pizzi M, Memo M, Spano P. Opposing regulation of amyloid precursor protein by ionotropic and metabotropic glutamate receptors. Neuroreport. 1995 Jun 19;6(9):1317–1321. [PubMed]
  • Lee RK, Wurtman RJ, Cox AJ, Nitsch RM. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8083–8087. [PMC free article] [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • Protein
    Protein
    Published protein sequences
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...